000168703 001__ 168703
000168703 005__ 20260217214838.0
000168703 0247_ $$2doi$$a10.1016/j.senol.2020.06.006
000168703 0248_ $$2sideral$$a119217
000168703 037__ $$aART-2021-119217
000168703 041__ $$aeng
000168703 100__ $$0(orcid)0000-0002-6811-6654$$aGascón Ruiz, M.
000168703 245__ $$aElderly breast cancer patients treated with Nab-paclitaxel: Results in real clinical practice
000168703 260__ $$c2021
000168703 5203_ $$aObjective: Clinical trials have shown that Nab-paclitaxel is more effective than paclitaxel in the treatment of metastatic breast cancer (MBC). Although the incidence of cancer increases with age, elderly patients are under-represented in clinical trials and tend to receive suboptimal treatment to avoid toxicity. The main aim of our study was to compare progression-free survival (PFS) among patients older and younger than 65 years treated with Nab-paclitaxel in real-world clinical practice. A secondary aim was to assess overall survival (OS) as well as the response rate and toxicity. Methods and patients: This single-centre study retrospectively analyzed a cohort of 60 patients with MBC treated with Nab-paclitaxel monotherapy in Hospital Clínico Lozano Blesa de Zaragoza. Results: The median PFS was 5.92 months (3.62–11.2) in patients < 65 years and was 5.06 months (4.31–12.4) in those =65 years (p = 0.868). The median OS was 26.9 months (18.6–30.7) in patients < 65 years and was 20.3 months (11.4–33.6) in those =65 years (p = 0.138). Conclusions: Although patients in the cohort studied had a median age of 60.45 years, which is higher than the median age in most clinical trials, PFS and OS in conditions of real-world clinical practice were similar to previously published data. The results of the use of Nab-paclitaxel in patients older than 65 years are similar to those in younger patients, with no additional toxicity problems. The results of our study agree with those of other notable studies.
000168703 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000168703 592__ $$a0.118$$b2021
000168703 593__ $$aObstetrics and Gynecology$$c2021$$dQ4
000168703 593__ $$aSurgery$$c2021$$dQ4
000168703 593__ $$aOncology$$c2021$$dQ4
000168703 594__ $$a0.3$$b2021
000168703 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000168703 700__ $$0(orcid)0000-0001-6883-8940$$aCasas Deza, D.
000168703 700__ $$0(orcid)0000-0001-8471-3224$$aLafuente Blasco, M.$$uUniversidad de Zaragoza
000168703 700__ $$aSesma Goñi, A.
000168703 700__ $$aCruellas Lapeña, M.
000168703 700__ $$aAlonso Martín, N.
000168703 700__ $$aZapata García, M.
000168703 700__ $$aOcáriz Diez, M.
000168703 700__ $$aZurera Berjaga, M.
000168703 700__ $$aQuilez Bielsa, E.
000168703 700__ $$aMurillo Jaso, L.
000168703 700__ $$0(orcid)0000-0003-0123-4274$$aAndrés Conejero, R.$$uUniversidad de Zaragoza
000168703 7102_ $$12007$$2265$$aUniversidad de Zaragoza$$bDpto. Métodos Estadísticos$$cÁrea Estadís. Investig. Opera.
000168703 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000168703 773__ $$g34, 2 (2021), 93-99$$pRev. senol. patol. mamar.$$tRevista de Senologia y Patologia Mamaria$$x0214-1582
000168703 8564_ $$s808337$$uhttps://zaguan.unizar.es/record/168703/files/texto_completo.pdf$$yVersión publicada
000168703 8564_ $$s1887599$$uhttps://zaguan.unizar.es/record/168703/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000168703 909CO $$ooai:zaguan.unizar.es:168703$$particulos$$pdriver
000168703 951__ $$a2026-02-17-20:13:45
000168703 980__ $$aARTICLE